Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joep C Defesche

Showing results (51-60 of 96) with videos related to

Pageof 10
Sort By:
The American Journal of Cardiology|January 27, 2009
Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemiaJeroen B van der Net, A Cecile J W Janssens, Joep C Defesche, et al.
Atherosclerosis|November 14, 2021
Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemiaTycho R Tromp, Arjen J Cupido, Laurens F Reeskamp, et al.
Journal of Clinical Lipidology|September 1, 2016
Children with hypercholesterolemia of unknown cause: Value of genetic risk scoresBarbara Sjouke, Michael W T Tanck, Sigrid W Fouchier, et al.
Journal of Clinical Lipidology|November 3, 2020
Corrigendum to "Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia" J Clin Lipidol 11 (2017) 1338-1346Joep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
Journal of Clinical Lipidology|October 2, 2017
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemiaJoep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
Atherosclerosis|December 6, 2022
Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemiaTycho R Tromp, Shirin Ibrahim, Nick S Nurmohamed, et al.
Ebiomedicine|October 23, 2020
Differential DNA methylation in familial hypercholesterolemiaLaurens F Reeskamp, Andrea Venema, Joao P Belo Pereira, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 10, 2005
Genetic determinants of cardiovascular disease risk in familial hypercholesterolemiaAngelique C M Jansen, Emily S van Aalst-Cohen, Michael W T Tanck, et al.
Journal of Clinical Lipidology|February 4, 2018
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemiaMerel L Hartgers, Joep C Defesche, Gisle Langslet, et al.
European Heart Journal|January 18, 2013
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoproteinVincenzo Sorrentino, Sigrid W Fouchier, Mohammad M Motazacker, et al.
Pageof 10

Showing results (51-60 of 96) with videos related to

Sort By:
Pageof 10
The American Journal of Cardiology|January 27, 2009
Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemiaJeroen B van der Net, A Cecile J W Janssens, Joep C Defesche, et al.
Atherosclerosis|November 14, 2021
Assessment of practical applicability and clinical relevance of a commonly used LDL-C polygenic score in patients with severe hypercholesterolemiaTycho R Tromp, Arjen J Cupido, Laurens F Reeskamp, et al.
Journal of Clinical Lipidology|September 1, 2016
Children with hypercholesterolemia of unknown cause: Value of genetic risk scoresBarbara Sjouke, Michael W T Tanck, Sigrid W Fouchier, et al.
Journal of Clinical Lipidology|November 3, 2020
Corrigendum to "Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemia" J Clin Lipidol 11 (2017) 1338-1346Joep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
Journal of Clinical Lipidology|October 2, 2017
Efficacy of alirocumab in 1191 patients with a wide spectrum of mutations in genes causative for familial hypercholesterolemiaJoep C Defesche, Claudia Stefanutti, Gisle Langslet, et al.
Atherosclerosis|December 6, 2022
Use of Lipoprotein(a) to improve diagnosis and management in clinical familial hypercholesterolemiaTycho R Tromp, Shirin Ibrahim, Nick S Nurmohamed, et al.
Ebiomedicine|October 23, 2020
Differential DNA methylation in familial hypercholesterolemiaLaurens F Reeskamp, Andrea Venema, Joao P Belo Pereira, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 10, 2005
Genetic determinants of cardiovascular disease risk in familial hypercholesterolemiaAngelique C M Jansen, Emily S van Aalst-Cohen, Michael W T Tanck, et al.
Journal of Clinical Lipidology|February 4, 2018
Alirocumab efficacy in patients with double heterozygous, compound heterozygous, or homozygous familial hypercholesterolemiaMerel L Hartgers, Joep C Defesche, Gisle Langslet, et al.
European Heart Journal|January 18, 2013
Identification of a loss-of-function inducible degrader of the low-density lipoprotein receptor variant in individuals with low circulating low-density lipoproteinVincenzo Sorrentino, Sigrid W Fouchier, Mohammad M Motazacker, et al.
Pageof 10